| David W Lazan, MD | |
|
2400 Mount Zion Pkwy, Jonesboro, GA 30236-2500 | |
| (404) 365-0966 | |
| Not Available |
| Full Name | David W Lazan |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 40 Years |
| Location | 2400 Mount Zion Pkwy, Jonesboro, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871568303 | NPI | - | NPPES |
| 064721700 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 208800000X (Florida) | Secondary |
| 208800000X | Urology | 078072 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Albany Urology Clinic | 2365423647 | 6 |
News Archive
Scientists at The University of Manchester have identified a protein that appears to hold the key to creating more effective drug treatments for melanoma, one of the deadliest cancers.
Predicting the beginning of influenza outbreaks is notoriously difficult, and can affect prevention and control efforts.
Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has signed a non-exclusive license agreement with GlaxoSmithKline ("GSK"). Under the terms of the agreement, GSK gains certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. Payments will be made to Response Genetics upon achivement of agreed-to milestones.
A study conducted by researchers at Kansas State University is the first to demonstrate increases in both self-control and timing precision as a result of a time-based intervention. This new research may be an important clue for developing behavioral approaches to treat disorders like attention deficit hyperactivity disorder, substance abuse and obesity.
An artificial-intelligence approach created at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy can teach itself to design new drug molecules from scratch and has the potential to dramatically accelerate the design of new drug candidates.
› Verified 7 days ago
| Entity Name | The Southeast Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245266956 PECOS PAC ID: 6204829013 Enrollment ID: O20040407000370 |
News Archive
Scientists at The University of Manchester have identified a protein that appears to hold the key to creating more effective drug treatments for melanoma, one of the deadliest cancers.
Predicting the beginning of influenza outbreaks is notoriously difficult, and can affect prevention and control efforts.
Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has signed a non-exclusive license agreement with GlaxoSmithKline ("GSK"). Under the terms of the agreement, GSK gains certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. Payments will be made to Response Genetics upon achivement of agreed-to milestones.
A study conducted by researchers at Kansas State University is the first to demonstrate increases in both self-control and timing precision as a result of a time-based intervention. This new research may be an important clue for developing behavioral approaches to treat disorders like attention deficit hyperactivity disorder, substance abuse and obesity.
An artificial-intelligence approach created at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy can teach itself to design new drug molecules from scratch and has the potential to dramatically accelerate the design of new drug candidates.
› Verified 7 days ago
| Entity Name | Albany Urology Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043383623 PECOS PAC ID: 2365423647 Enrollment ID: O20040525000606 |
News Archive
Scientists at The University of Manchester have identified a protein that appears to hold the key to creating more effective drug treatments for melanoma, one of the deadliest cancers.
Predicting the beginning of influenza outbreaks is notoriously difficult, and can affect prevention and control efforts.
Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has signed a non-exclusive license agreement with GlaxoSmithKline ("GSK"). Under the terms of the agreement, GSK gains certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. Payments will be made to Response Genetics upon achivement of agreed-to milestones.
A study conducted by researchers at Kansas State University is the first to demonstrate increases in both self-control and timing precision as a result of a time-based intervention. This new research may be an important clue for developing behavioral approaches to treat disorders like attention deficit hyperactivity disorder, substance abuse and obesity.
An artificial-intelligence approach created at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy can teach itself to design new drug molecules from scratch and has the potential to dramatically accelerate the design of new drug candidates.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David W Lazan, MD 3495 Piedmont Rd Ne, Atlanta, GA 30305-1717 Ph: (404) 364-7285 | David W Lazan, MD 2400 Mount Zion Pkwy, Jonesboro, GA 30236-2500 Ph: (404) 365-0966 |
News Archive
Scientists at The University of Manchester have identified a protein that appears to hold the key to creating more effective drug treatments for melanoma, one of the deadliest cancers.
Predicting the beginning of influenza outbreaks is notoriously difficult, and can affect prevention and control efforts.
Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has signed a non-exclusive license agreement with GlaxoSmithKline ("GSK"). Under the terms of the agreement, GSK gains certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. Payments will be made to Response Genetics upon achivement of agreed-to milestones.
A study conducted by researchers at Kansas State University is the first to demonstrate increases in both self-control and timing precision as a result of a time-based intervention. This new research may be an important clue for developing behavioral approaches to treat disorders like attention deficit hyperactivity disorder, substance abuse and obesity.
An artificial-intelligence approach created at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy can teach itself to design new drug molecules from scratch and has the potential to dramatically accelerate the design of new drug candidates.
› Verified 7 days ago
Dr. Chinonyerem Uzoamaka Okoro, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Mount Zion Pkwy, Jonesboro, GA 30236 Phone: 770-603-3562 Fax: 770-603-3819 |